Hillary Clinton sent biotech stocks plunging Tuesday as she rolled out her plan to limit drug prices. A Journal editorial notes that Mrs. Clinton also intends to “set quotas for research and development, though one of five U.S. R&D dollars are deployed by drug makers.” She will unfortunately find a receptive audience. In a recent survey nearly three-quarters of respondents said they believed drug costs are “unreasonable.” Cancer drugs consume just 1% of U.S. health spending, but when prices seem high it can be easy to forget about benefits. “Two-thirds of Americans now survive at least five years after a cancer...